Table 2.

Results of Trial Group Analyses for Survival

Variable	Main Analysis (13 trials)
	HR	95% CI	Interaction P
Planned chemotherapy type
Platinum based	0.84	0.72 to 0.98
Nonplatinum based	0.76	0.62 to 0.94	.48
Planned radiotherapy dose
≥ 45 Gy + BRT	0.78	0.68 to 0.89
< 45 Gy + BRT	0.93	0.70 to 1.24	.26
Planned radiotherapy duration, weeks
≤ 8	0.83	0.72 to 0.96
> 8	0.73	0.57 to 0.93	.35
Planned chemotherapy cycle length, weeks*
≤ 1	0.74	0.60 to 0.92
> 1	0.95	0.72 to 1.25	.16
Planned cisplatin dose-intensity, mg/m2/wk*
≤ 25	0.93	0.70 to 1.24
> 25	0.76	0.62 to 0.96	.25
Cisplatin regimen*
Single agent	0.76	0.62 to 0.93
Combination	0.93	0.70 to 1.24	.25
Chemotherapy regimen
Single agent	0.75	0.63 to 0.88
Combination	0.86	0.71 to 1.04	.29

NOTE. Two trials in which additional adjuvant chemotherapy was administered on the treatment arm are excluded.

^*Results are based only on trials in which cisplatin-based chemoradiation was administered.